HDAC6, a member of class IIB, is mainly localized in cytoplasm and deacetylates non-histone proteins,
unlike other HDACs.
In this way, HDAC6 regulates various cellular processes including cell growth, cell migration, intracellular transport, and even cell death.
Moreover, HDAC6 plays a role in the clearance of ubiquitinated proteins by its ubiquitin-binding domain. Chong Kun Dang Research Institute have been focusing on developing HDAC6 inhibitors as drugs for various diseases related in neurology, oncology, immunology by the platform technology based on various scaffolds.
|Neurology||Improvement of cognition and motor function through enhancing axonal transport|
|Oncology||Cancer death by increasing endoplasmic reticulum stress|
|Immunology||Treatment of autoimmune diseases through anti-inflammation|
Liquistal® is a liquid formulation containing a drug for injection,
and it is transformed to a gel when contacted with body fluids after subcutaneous injection.
The gel formed after subcutaneous injection possesses a lattice structure like a honeycomb and
allows the drug to be released steadily over extended period. Currently, PLGA is the only material for sustained release injection with FDA approval, but it has problems with the fact that manufacturing process is not simple and that inflammatory response and pain can occur by PLGA injection.
Liquistal® is the technology which overcomes such shortcomings of PLGA, and it offers a simple
manufacturing process, improved sustainability and safety. Also it can be applied to the delivery
of various kinds of drugs including chemicals, proteins and peptides.
The safety of Liquistal® formulations was confirmed through preclinical studies,
and a phase I clinical trial is currently underway.